IHC
CytoDyn to Study Leronlimab in Certain CCR5-Positive Metastatic Colorectal Cancer Patients
The firm met with the FDA to align on plans for a trial of leronlimab, trifluridine, TAS-102, and bevacizumab in microsatellite stable, CCR5-expressing mCRC.
FDA Approves AstraZeneca's Imfinzi, Chemotherapy for MMR-Deficient Endometrial Cancer
The agency based its approval on the results of the DUO-E clinical trial, in which the immunotherapy-chemo combination improved progression-free survival.
Roche PD-L1 Assay Nabs Expanded CE Mark as CDx for Libtayo, Chemotherapy Combo
The Ventana assay previously received CE marking for identifying patients with lung cancer who may benefit from treatment with Libtayo.
Researchers at ASCO presented data on the genomic differences in tumors based on IHC and imaging, between racial groups, and between primary and metastatic lesions.
AstraZeneca and Daiichi Sankyo will discuss with regulators the latest DESTINY-Breast06 data presented at ASCO in the hopes of expanding Enhertu's indication.